

individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:* National Diabetes and Digestive and Kidney Diseases Advisory Council.

*Date:* January 28, 2015.

*Open:* 8:30 a.m. to 12:00 p.m.

*Agenda:* To present the Director's Report and other scientific presentations.

*Place:* National Institutes of Health, Building 31, Conference Room 10, 31 Center Drive, Bethesda, MD 20892.

*Closed:* 3:45 p.m. to 4:00 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* National Institutes of Health, Building 31, Conference Room 10, 31 Center Drive, Bethesda, MD 20892.

*Contact Person:* Brent B. Stanfield, Ph.D., Director, Division of Extramural Activities, National Institutes of Diabetes and Digestive and Kidney Diseases, 6707 Democracy Blvd., Room 715, MSC 5452, Bethesda, MD 20892, (301) 594-8843, [stanfibr@nidk.nih.gov](mailto:stanfibr@nidk.nih.gov).

*Name of Committee:* National Diabetes and Digestive and Kidney Diseases Advisory Council; Diabetes, Endocrinology and Metabolic Diseases Subcommittee.

*Date:* January 28, 2015.

*Open:* 1:00 p.m. to 2:30 p.m.

*Agenda:* To review the Division's scientific and planning activities.

*Place:* National Institutes of Health, Building 31, Conference Room 10, 31 Center Drive, Bethesda, MD 20892.

*Closed:* 2:30 p.m. to 4:00 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* National Institutes of Health, Building 31, Conference Room 10, 31 Center Drive, Bethesda, MD 20892.

*Contact Person:* Brent B. Stanfield, Ph.D., Director, Division of Extramural Activities, National Institutes of Diabetes and Digestive and Kidney Diseases, 6707 Democracy Blvd., Room 715, MSC 5452, Bethesda, MD 20892, (301) 594-8843, [stanfibr@nidk.nih.gov](mailto:stanfibr@nidk.nih.gov).

*Name of Committee:* National Diabetes and Digestive and Kidney Diseases Advisory Council; Kidney, Urologic and Hematologic Diseases Subcommittee.

*Date:* January 28, 2015.

*Open:* 1:00 p.m. to 3:00 p.m.

*Agenda:* To review the Division's scientific and planning activities.

*Place:* National Institutes of Health, Building 31, Conference Room 7, 31 Center Drive, Bethesda, MD 20892.

*Closed:* 3:00 p.m. to 4:00 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* National Institutes of Health, Building 31, Conference Room 7, 31 Center Drive, Bethesda, MD 20892.

*Contact Person:* Brent B. Stanfield, Ph.D., Director, Division of Extramural Activities, National Institutes of Diabetes and Digestive and Kidney Diseases, 6707 Democracy Blvd., Room 715, MSC 5452, Bethesda, MD 20892, (301) 594-8843, [stanfibr@nidk.nih.gov](mailto:stanfibr@nidk.nih.gov).

*Name of Committee:* National Diabetes and Digestive and Kidney Diseases Advisory

Council; Digestive Diseases and Nutrition Subcommittee.

*Date:* January 28, 2015.

*Open:* 1:00 p.m. to 2:30 p.m.

*Agenda:* To review the Division's scientific and planning activities.

*Place:* National Institutes of Health, Building 31, Conference Room 6, 31 Center Drive, Bethesda, MD 20892.

*Closed:* 2:30 p.m. to 4:00 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* National Institutes of Health, Building 31, Conference Room 6, 31 Center Drive, Bethesda, MD 20892.

*Contact Person:* Brent B. Stanfield, Ph.D., Director, Division of Extramural Activities, National Institutes of Diabetes and Digestive and Kidney Diseases, 6707 Democracy Blvd., Room 715, MSC 5452, Bethesda, MD 20892, (301) 594-8843, [stanfibr@nidk.nih.gov](mailto:stanfibr@nidk.nih.gov).

Any interested person may file written comments with the committee by forwarding the statement to the Contact Person listed on this notice. The statement should include the name, address, telephone number and when applicable, the business or professional affiliation of the interested person.

In the interest of security, NIH has instituted stringent procedures for entrance onto the NIH campus. All visitor vehicles, including taxicabs, hotel, and airport shuttles will be inspected before being allowed on campus. Visitors will be asked to show one form of identification (for example, a government-issued photo ID, driver's license, or passport) and to state the purpose of their visit.

Information is also available on the Institute's/Center's home page: [www.nidk.nih.gov/fund/divisions/DEA/Council/coundesc.htm](http://www.nidk.nih.gov/fund/divisions/DEA/Council/coundesc.htm), where an agenda and any additional information for the meeting will be posted when available.

(Catalogue of Federal Domestic Assistance Program Nos. 93.847, Diabetes, Endocrinology and Metabolic Research; 93.848, Digestive Diseases and Nutrition Research; 93.849, Kidney Diseases, Urology and Hematology Research, National Institutes of Health, HHS)

Dated: December 5, 2014.

**David Clary,**

*Program Analyst, Office of Federal Advisory Committee Policy.*

[FR Doc. 2014-29020 Filed 12-10-14; 8:45 am]

**BILLING CODE 4140-01-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### National Institute of Allergy and Infectious Diseases; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the

provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:* National Institute of Allergy and Infectious Diseases Special Emphasis Panel; NIH Support for Conferences and Scientific Meetings (R13/U13).

*Date:* January 6, 2015.

*Time:* 8:00 a.m. to 5:00 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* 5601 Fishers Lane, Rockville, MD 20852, (Telephone Conference Call).

*Contact Person:* Vasundhara Varthakavi, DVM, Ph.D., Scientific Review Officer, Scientific Review Program, DEA/NIAID/NIH/DHHS, Room 3E70B, 5601 Fishers Lane, Rockville, MD 20852, 240-669-5020, [varthakaviv@niaid.nih.gov](mailto:varthakaviv@niaid.nih.gov).

(Catalogue of Federal Domestic Assistance Program Nos. 93.855, Allergy, Immunology, and Transplantation Research; 93.856, Microbiology and Infectious Diseases Research, National Institutes of Health, HHS)

Dated: December 5, 2014.

**David Clary,**

*Program Analyst, Office of Federal Advisory Committee Policy.*

[FR Doc. 2014-29019 Filed 12-10-14; 8:45 am]

**BILLING CODE 4140-01-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### National Institute of Neurological Disorders and Stroke; Notice of Closed Meetings

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meetings.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:* Neurological Sciences Training Initial Review Group; NST-1 Subcommittee.

*Date:* February 9-10, 2015.

Time: 8:00 a.m. to 6:00 p.m.

Agenda: To review and evaluate grant applications.

Place: One Washington Circle One Washington Circle NW., Washington, DC 20037.

Contact Person: Raul A. Saavedra, Ph.D., Scientific Review Officer, Scientific Review Branch, Division of Extramural Research, NINDS/NIH/DHHS/Neuroscience Center, 6001 Executive Boulevard, Suite 3208, MSC 9529, Bethesda, MD 20892-9529, 301-496-9223, [saavedr@ninds.nih.gov](mailto:saavedr@ninds.nih.gov).

Name of Committee: National Institute of Neurological Disorders and Stroke Initial Review Group; Neurological Sciences and Disorders A.

Date: March 2-3, 2015.

Time: 8:00 a.m. to 6:00 p.m.

Agenda: To review and evaluate grant applications.

Place: The Fairmont Olympic Hotel, 411 University Street, Seattle, WA 98101.

Contact Person: Natalia Strunnikova, Ph.D., Scientific Review Officer, Scientific Review Branch, Division of Extramural Research, NINDS/NIH/DHHS/Neuroscience Center, 6001 Executive Boulevard, Suite 3208, MSC 9529, Bethesda, MD 20892-9529, 301-402-0288, [natalia.strunnikova@nih.gov](mailto:natalia.strunnikova@nih.gov). (Catalogue of Federal Domestic Assistance Program Nos. 93.853, Clinical Research Related to Neurological Disorders; 93.854, Biological Basis Research in the Neurosciences, National Institutes of Health, HHS)

Dated: December 5, 2014.

**Carolyn Baum,**

Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2014-29021 Filed 12-10-14; 8:45 am]

BILLING CODE 4140-01-P

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### Interagency Coordinating Committee on the Validation of Alternative Methods Communities of Practice Webinar on Reverse Toxicokinetics; Notice of Public Webinar and Registration Information

**SUMMARY:** The Interagency Coordinating Committee on the Validation of Alternative Methods (ICCVAM) announces a public webinar “Reverse Toxicokinetics: Using *In Vitro* Data to Estimate Exposures that Could Be Associated with Adverse Effects *In Vivo*.” The webinar is organized on behalf of ICCVAM by the National Toxicology Program Interagency Center for the Evaluation Alternative Toxicological Methods (NICEATM) and hosted by the Environmental Protection Agency’s National Center for Computational Toxicology (NCCT). Interested persons may participate via

Adobe® Connect™. Time is allotted for questions from participants.

**DATES:** Webinar: January 27, 2015, 1:00 p.m. to approximately 2:30 p.m. Eastern Standard Time (EST).

Registration for Webinar: December 3, 2014, until 2:30 p.m. January 27, 2015.

**ADDRESSES:** Webinar Web page: <http://ntp.niehs.nih.gov/go/ivive-webinar>.

**FOR FURTHER INFORMATION CONTACT:** Dr. Warren S. Casey, Director, NICEATM; email: [warren.casey@nih.gov](mailto:warren.casey@nih.gov); telephone: (919) 316-4729.

#### SUPPLEMENTARY INFORMATION:

**Background:** ICCVAM promotes the development and validation of toxicity testing methods that protect human health and the environment while replacing, reducing, or refining animal use. ICCVAM also provides guidance to test method developers and facilitates collaborations that promote the development of new test methods. To address these goals, ICCVAM will hold the communities of practice webinar “Reverse Toxicokinetics: Using *In Vitro* Data to Estimate Exposures that Could Be Associated with Adverse Effects *In Vivo*.”

Many commercial and environmental chemicals lack toxicity data necessary for users and risk assessors to make fully informed decisions about potential health effects. Generating these data using high throughput *in vitro* cell- or biochemical-based tests would be faster and less expensive than testing in animals; tests that use human cells or cellular components would also potentially be more relevant to human health. However, correlating test chemical concentrations that produce effects *in vitro* to exposure levels that cause toxicity *in vivo* is complicated, since factors that can significantly influence toxicity *in vivo* (such as plasma protein binding and metabolic clearance) are often not replicated in *in vitro* assays. Mathematical models known as reverse toxicokinetic models provide a framework for making these correlations. Reverse toxicokinetic models provide an estimate of the exposure level that would result in a blood concentration equal to a chemical concentration causing an *in vitro* adverse outcome.

The ICCVAM webinar will feature presentations by two experts in the development and application of reverse toxicokinetic models to high throughput screening data: John Wambaugh, Ph.D., physical scientist at NCCT, and Barbara Wetmore, Ph.D., senior research investigator at the Hamner Institutes for Health Sciences. Their presentations will provide an overview of the development of reverse toxicokinetic

models and discuss the consideration of population variability and sensitive subpopulations in the use of these models.

**Webinar and Registration:** This webinar is open to the public with time scheduled following each presentation for questions by participants. Registration for the webinar is required and is open from December 3, 2014, through 2:30 p.m. on January 27, 2015. A link to registration is available at <http://ntp.niehs.nih.gov/go/ivive-webinar>. Registrants will receive instructions on how to access and participate in the webinar in the email confirming their registration.

The preliminary agenda is available at <http://ntp.niehs.nih.gov/go/ivive-webinar>. Interested individuals are encouraged to visit this Web page to stay abreast of the most current webinar information.

Individuals with disabilities who need accommodation to participate in this event should contact Ms. LaCresha Styles at phone: (919) 541-3282 or email: [styles.lacresha@epa.gov](mailto:styles.lacresha@epa.gov). TTY users should contact the Federal TTY Relay Service at (800) 877-8339. Requests should be made at least five business days in advance of the event.

**Background Information on ICCVAM and NICEATM:** ICCVAM is an interagency committee composed of representatives from 15 federal regulatory and research agencies that require, use, generate, or disseminate toxicological and safety testing information. The ICCVAM Authorization Act of 2000 (42 U.S.C. 285l-3) establishes ICCVAM as a permanent interagency committee of the National Institute of Environmental Health Sciences and provides the authority for ICCVAM’s involvement in activities relevant to the development of new and revised toxicological tests.

ICCVAM conducts technical evaluations of new, revised, and alternative test methods and integrated testing strategies with regulatory applicability and promotes the scientific validation and regulatory acceptance of test methods that both more accurately assess the safety and hazards of chemicals and products and replace, reduce, or refine (enhance animal well-being and lessen or avoid pain and distress) animal use. ICCVAM acts to ensure that new and revised test methods are validated to meet the needs of federal agencies, to increase the efficiency and effectiveness of federal agency test method review, and to optimize utilization of scientific expertise outside the federal government. Additional information